About Bruce KenKnight
Bruce KenKnight is chief executive officer of SymKardia. The company is developing selective cardiac neuromodulation as a way to treat cardiac arrhythmias. He has more than 30 years of leadership experience in medical devices for cardiology and neuromodulation.
Earlier, he was vice president of the Heart Failure Program, New Ventures at LivaNova, formerly Cyberonics. He was also president and chief executive officer of Valtech Cardio. At Boston Scientific, formerly Guidant, he was vice president of research and technology development and business development. He holds a bachelor's degree in mechanical engineering and a master's and doctorate in biomedical engineering from the University of Minnesota. He is an inventor on more than 600 issued and pending patents and an author of over 200 peer-reviewed publications.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Bruce KenKnight in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Bruce KenKnight works with at each company, as listed on that company's latest Form D.
